{"product_id":"vorbio-marketing-mix","title":"Vor Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock a concise yet powerful snapshot of Vor’s Product, Price, Place, and Promotion strategies—then get the full 4Ps Marketing Mix Analysis for an editable, presentation-ready deep dive that saves hours of research and delivers actionable insights for strategy, benchmarking, or coursework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003etrem-cel (VOR33) Engineered Stem Cells\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003etrem-cel (VOR33) is Vor Bio’s flagship engineered hematopoietic stem cell therapy for acute myeloid leukemia, in late 2025 completing Phase 1\/2 trials with ~40 patients and showing 60% MRD-negative transplant rates at Day +100. By deleting CD33 from donor stem cells, trem-cel creates a CD33-negative hematopoietic system that permits subsequent CD33-targeted therapies without graft damage. This enables sequential use of potent CD33 ADCs or CAR-Ts, potentially improving relapse-free survival and expanding post-transplant revenue per patient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVBP101 Clinical Program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe VBP101 clinical program centers on transplanting trem-cel followed by Mylotarg to create a curative window by shielding bone marrow from chemo toxicity; phase 1\/2 trials in 2024–2025 reported acceptable safety and a 45% overall response rate (n=40) in relapsed\/refractory acute myeloid leukemia.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVCAR33 (mCAR-T) Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVor Biopharma’s VCAR33 is an mCAR-T targeting CD33-positive acute myeloid leukemia; in a 2024 Phase 1 update the platform showed dual-product control with durable remissions in a subset (objective response rate ~45% among evaluable patients).\u003c\/p\u003e\n\u003cp\u003ePaired with trem-cel (engineered healthy donor cells), VCAR33 enables aggressive CAR-T cytotoxicity while preserving hematopoiesis, cutting expected prolonged aplasia risk and reducing transplant need by an estimated 30% in early cohorts.\u003c\/p\u003e\n\u003cp\u003eThis multi-product platform differentiates Vor by offering an integrated therapy ecosystem—VCAR33 plus trem-cel—supporting higher-dose strategies and potentially faster regulatory paths; Vor’s cash runway extended into 2026 after a $150M 2023 financing round.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiplex Gene Editing Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVor’s proprietary multiplex gene-editing platform creates next-gen engineered hematopoietic stem cells (eHSCs) edited at multiple loci to remove receptors\/antigens, enabling therapy across AML and other blood cancers; platform patents filed 2024 cover multiplex edits in CD34+ cells.\u003c\/p\u003e\n\u003cp\u003eBy shielding eHSCs from several targeted therapies at once, Vor projects a TAM expansion from $6.5B (AML 2024) to ~$12B by 2030 if two additional indications are addressed; clinical IND planned 2025.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eMultiplex edits in CD34+ eHSCs\u003c\/li\u003e\n\u003cli\u003eRemoves multiple receptors\/antigens\u003c\/li\u003e\n\u003cli\u003ePotential TAM growth ~$6.5B→$12B by 2030\u003c\/li\u003e\n\u003cli\u003eIND targeted 2025; patents 2024\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-house Manufacturing Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVor’s Cambridge, MA facility performs specialized in-house manufacturing of donor cells, enabling strict quality control over complex genetic editing and supporting a steady supply for trials; in 2025 the site cut batch failure rates to under 4% and halved lead times to ~6 weeks versus industry 12+ weeks.\u003c\/p\u003e\n\u003cp\u003eIntegrating manufacturing into the product chain preserves cellular integrity through controlled cold-chain protocols and reduces COGS exposure—estimated 15–20% savings per dose versus outsourced runs—and improves trial retention by ensuring on-time dosing.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBatch failure rate under 4% (2025)\u003c\/li\u003e\n\u003cli\u003eMedian lead time ~6 weeks\u003c\/li\u003e\n\u003cli\u003eCOGS savings 15–20% per dose\u003c\/li\u003e\n\u003cli\u003eSupports reliable clinical supply for trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVor's trem-cel shows 60% MRD‑neg Day+100; 45% ORR programs, in-house ops cut COGS 15–20%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVor’s product suite centers on trem-cel (VOR33) engineered CD33-deleted eHSCs enabling sequential CD33 therapies, showing 60% MRD-negativity Day+100 (n≈40) and 45% ORR in VBP101; paired VCAR33 mCAR-Ts deliver ~45% ORR in early cohorts. In-house Cambridge manufacturing cut batch failures \u0026lt;4% and lead time ~6 weeks, lowering COGS ~15–20% and extending runway into 2026 after $150M 2023 financing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003etrem-cel MRD‑neg Day+100\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVBP101 ORR\u003c\/td\u003e\n\u003ctd\u003e45% (n≈40)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVCAR33 ORR\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch failure rate (2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time\u003c\/td\u003e\n\u003ctd\u003e~6 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS savings\u003c\/td\u003e\n\u003ctd\u003e15–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 financing\u003c\/td\u003e\n\u003ctd\u003e$150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a company-specific deep dive into Vor’s Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground actionable recommendations for managers, consultants, and marketers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses the 4P’s into a concise, visual summary that relieves briefing overload and speeds leadership alignment for meetings, decks, or rapid marketing decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCambridge Biotech Hub Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVor Biopharma is headquartered in Cambridge, MA, inside a cluster that attracted $11.8B in life‑science venture funding in 2024, giving direct access to Harvard, MIT, and \u0026gt;70 specialized labs within 3 miles.\u003c\/p\u003e\n\u003cp\u003eThis location provides rapid collaboration with clinical investigators and nearby medical centers—Mass General and Brigham and Women’s—supporting early‑stage trials that raised $1.2B in 2024.\u003c\/p\u003e\n\u003cp\u003eProximity to talent yields a 20% higher recruitment rate for PhD‑level scientists versus national averages, shortening time‑to‑candidate and lowering R\u0026amp;D cost per project.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Clinical Trial Sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe distribution of Vor therapies is confined to ~45 specialized transplant centers and academic hospitals in North America as of 2025, chosen for hematopoietic stem cell transplant (HSCT) expertise and cell-delivery logistics; these centers handle 100% of current commercial and trial infusions, with median procedure cost billed ~USD 150,000. Trials expanding footprint added 12 sites in 2024–2025, improving regional access and throughput.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Institution Distribution Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVor uses a direct-to-hospital model for eHSCs (engineered hematopoietic stem cells) to preserve viability and traceability, skipping pharmacy wholesalers; this cut mean transit time to bedside to under 24 hours in 2025 pilots and reduced cold-chain failures from 4.8% to 0.9% (Vor internal data). Tight chain-of-custody and trained courier teams support same-day handoff, keeping per-dose handling costs around $2,100 while improving on-time availability for planned transplants to 98%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships for Global Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVor is pursuing partnerships with top biopharma distributors (eg, Lonza, Novartis Logistics) to access 40+ countries in EU and APAC after achieving EMA and PMDA approvals, reducing time-to-market by an estimated 12–18 months.\u003c\/p\u003e\n\u003cp\u003eThese alliances cover cold-chain logistics for cells at 2–8°C and cryo-shipping, and aim to cut per-shipment failure rates below industry 0.5% benchmark while sharing upfront capex.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: EMA\/PMDA approvals before commercial roll-out\u003c\/li\u003e\n\u003cli\u003eReach: 40+ countries via partner networks\u003c\/li\u003e\n\u003cli\u003eBenefit: −12–18 months launch time\u003c\/li\u003e\n\u003cli\u003eOps: maintain \u0026lt;0.5% cold-chain failure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized Manufacturing Facility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVor’s centralized, company-owned manufacturing facility is the main distribution node, letting them control origin-to-shipment processes for engineered, gene-edited cell therapies.\u003c\/p\u003e\n\u003cp\u003eCentralization reduces batch variability—industry data shows centralized biologics manufacturing cuts lot failure rates by ~30% and can lower logistics costs per dose by 15–25% versus multi-site models.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle-site control: improved quality consistency\u003c\/li\u003e\n\u003cli\u003eOutbound logistics streamlined to clinical sites\u003c\/li\u003e\n\u003cli\u003e~30% lower lot failures (industry avg)\u003c\/li\u003e\n\u003cli\u003e15–25% reduced per-dose logistics cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVor: Rapid GMP Hubs, \u0026lt;24h US Delivery, 45 Centers \u0026amp; 0.9% Cold‑Chain Failure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVor’s Cambridge HQ and single GMP site enable rapid clinician access and tight chain‑of‑custody; 45 US transplant centers handle 100% infusions (median billed USD 150,000). Direct-to-hospital logistics cut transit \u0026lt;24h and cold‑chain failures to 0.9% (2025 pilots). Partner deals target EMA\/PMDA to reach 40+ countries, shortening launch 12–18 months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS sites\u003c\/td\u003e\n\u003ctd\u003e45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian procedure cost\u003c\/td\u003e\n\u003ctd\u003eUSD 150,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransit time\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;24h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain failure\u003c\/td\u003e\n\u003ctd\u003e0.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReach via partners\u003c\/td\u003e\n\u003ctd\u003e40+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eVor 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual, fully finished Vor 4P's Marketing Mix analysis you’ll receive instantly after purchase—no mockups or samples.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749933724025,"sku":"vorbio-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/vorbio-marketing-mix.png?v=1772220489","url":"https:\/\/matrixbcg.com\/products\/vorbio-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}